市場調査レポート

商品コード

1490318

CAR-T細胞療法市場（第5版）：業界動向と世界の予測（～2035年） - 標的抗原別、適応症別、主要地域別、薬剤売上予測、主要企業

CAR T-cell therapy market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Antigen, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

出版日: 2024年03月08日 | 発行: Roots Analysis

| ページ情報: 英文 640 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 744,468円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,085,754円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,644,222円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,792,184円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.13円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

CAR-T細胞療法の市場規模は、2024年に46億米ドルになるとみられ、2024年～2035年の予測期間中に20％のCAGRで拡大すると予測されています。

がんは世界的に主要な死亡原因であり、世界保健機関（WHO）は2020年だけで1,000万人のがん関連死が発生すると報告しています。予測によると、2040年までに世界のがん負担は増大し、新たに2,750万人が罹患すると推定され、罹患した個人、家族、地域社会、国の医療制度に肉体的、精神的、経済的に莫大な負担がかかることになります。現在、さまざまながんに対して、化学療法、放射線療法、手術といった従来の治療法が用いられています。しかし、疾患の進行を抑制し、悪性細胞の転移を阻止することを目的とした治療の選択肢は数多くあるにもかかわらず、永続的な寛解を達成することは依然として困難です。従来の治療の限界に対応するため、より標的を絞った抗がん剤治療の開発に積極的な取り組みが開始されています。なかでもCAR-T細胞療法は、治療関連の副作用を最小限に抑えながら腫瘍細胞を排除する能力を持つことから、有望な選択肢として浮上しています。免疫療法は、身体の免疫システムやその構成要素を活用してがんと闘うものです。治療用がんワクチン、腫瘍溶解性ウイルス、サイトカイン、免疫チェックポイント阻害剤、特定の全細胞ベース療法など、様々なクラスの免疫療法が、がん管理や治療の選択肢として浮上しています。

CAR-T細胞療法は、抗がん剤治療に最近追加されたもので、モノクローナル抗体や結合抗体などの標的抗体ベースの治療薬と並んで大きな成功を示しています。ヒト免疫系の多彩なエフェクター機構を利用したこの特異性の高い細胞療法は、世界的にがん治療に革命をもたらしています。この分野での継続的な研究は、新規の分子標的を発見し続けており、この分野の企業の研究パイプラインを強化しています。開発中のCAR-T細胞療法や市場に参入するCAR-T細胞療法の数が増加していることから、CAR-T細胞療法市場はバイオ医薬品業界において最も価値のある分野の1つになる見通しです。

当レポートでは、世界のCAR-T細胞療法市場について調査し、市場の概要とともに、標的抗原別、適応症別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 5.1 Key Characteristics of CAR-T Cells
Table 5.2 Comparison of First and Second-Generation CAR-Ts
Table 6.1 CAR-T Cell Therapies: Approved and Clinical Pipeline
Table 6.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-cell, Dosage Regimen, and Target Patient Population
Table 6.3 CAR-T Cell Therapy: Preclinical Pipeline
Table 6.4 List of CAR-T Cells Developers
Table 10.1 Leading CAR-T Cell Therapy Developers
Table 10.2 Autolus: Company Profile
Table 10.3 bluebird Bio: Company Profile
Table 10.4 Bristol Myers Squibb: Company Profile
Table 10.5 CARsgen Therapeutics: Company Profile
Table 10.6 Cellectis: Company Profile
Table 10.7 Gilead Sciences: Company Profile
Table 10.8 Innovative Cellular Therapeutics: Company Profile
Table 10.9 Noile-Immune Biotech: Company Profile
Table 10.10 Novartis: Company Profile
Table 10.11 Sinobioway Cell Therapy: Company Profile
Table 10.12 Takara Bio: Company Profile
Table 10.13 Wellington Zhaotai Therapies: Company Profile
Table 11.1 CAR T Cell Therapy: List of Partnerships and Collaborations, 2000-2022
Table 12.1 CAR T Cell Therapies: Funding and Investments, 2018-2024
Table 12.2 CAR T Cell Therapies: Summary of Investments
Table 13.1 Patent Analysis: Prominent CPC Sections
Table 13.2 Patent Analysis: Most Popular CPC Symbols
Table 13.3 Patent Analysis: List of Top CPC Symbols
Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.1 Assessment Strategies for Different Manufacturing Processes
Table 14.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 14.3 Cell Therapy Manufacturing: Companies with In-house Capabilities and Contract Manufacturers
Table 15.1 Price of Marketed Gene / Cell Therapies
Table 15.2 Price of Marketed Targeted Drugs
Table 15.3 CAR-T Cell Therapy: Expert Opinions on Pricing
Table 15.4 CAR-T Cell Therapy: Reimbursement Landscape
Table 21.1 CAR-T Cell Therapy: List of Forecasted Molecules
Table 25.1 CAR-T Cell Therapy: Distribution by Stage of Development
Table 25.2 CAR-T Cell Therapy: Distribution by Type of Therapy
Table 25.3 CAR-T Cell Therapy: Distribution by Target Antigen
Table 25.4 CAR-T Cell Therapy: Distribution by Target Indication
Table 25.5 CAR-T Cell Therapy: Distribution by Target Therapeutic Area
Table 25.6 CAR-T Cell Therapy: Distribution by Stage of Development and Therapeutic Area
Table 25.7 CAR-T Cell Therapy: Distribution by Source of T- cells
Table 25.8 CAR-T Cell Therapy: Distribution by Stage of Development and Source of T- cells
Table 25.9 CAR-T Cell Therapy: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapy: Distribution by Dosage Regimen
Table 25.11 CAR-T Cell Therapy: Distribution by Target Patient Population
Table 25.12 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region wise)
Table 25.17 CAR-T Cell Therapy: Distribution by Location of Headquarters (Country wise)
Table 25.18 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Table 25.19 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Table 25.20 CAR-Construction: Distribution by Generation of CAR
Table 25.21 CAR-Construction: Distribution by Type of scFv Antibody Used
Table 25.22 CAR-Construction: Distribution by Type of Virus Used
Table 25.23 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Table 25.24 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Table 25.25 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2017-2024
Table 25.26 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Pre- 2017-2024
Table 25.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 25.28 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 25.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2017-2024
Table 25.30 Clinical Trial Analysis: Distribution by Trial Status
Table 25.31 Clinical Trial Analysis: Distribution by Patient Gender
Table 25.32 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 25.33 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 25.34 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 25.35 Clinical Trial Analysis: Distribution by Trial Purpose
Table 25.36 Clinical Trial Analysis: Distribution by Design Allocation
Table 25.37 Leading Industry Players: Distribution by Number of Registered Trials
Table 25.38 Leading Non-industry Players: Distribution by Number of Registered Trials
Table 25.39 Clinical Trial Analysis: Distribution of Clinical Trials by Status and Geography
Table 25.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 25.41 KOL Analysis: Distribution by Type of Organization
Table 25.42 KOL Analysis: Distribution by Affiliated Organization
Table 25.43 KOL Analysis: Distribution by Qualification
Table 25.44 CAR T-Cell Therapies: Geographical Distribution of KOLs
Table 25.45 Most Prominent KOLs: Distribution by RA Score
Table 25.46 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.47 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015-2022
Table 25.48 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.49 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 25.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 25.51 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.52 Partnership and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.53 Most Popular Therapies: Distribution by Number of Partnerships
Table 25.54 Most Active Industry Players: Distribution by Number of Partnerships
Table 25.55 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 25.56 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 25.57 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 25.58 Funding and Investment: Cumulative Distribution of Instances by Year, Pre 2014-2024
Table 25.59 Funding and Investment: Cumulative Distribution of Amount Invested by Year, Pre-2014-2024 (USD Million)
Table 25.60 Funding and Investment: Distribution of Instances by Type of Funding
Table 25.61 Funding and Investment: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.62 Funding and Investment: Distribution by Amount Invested and Type of Funding Year Wise
Table 25.63 Funding and Investment: Distribution by Geography (Region)
Table 25.64 Funding and Investment: Distribution by Geography (Country)
Table 25.65 Most Active Players: Distribution by Lead Investors
Table 25.66 Most Active Players: Distribution by Number of Funding Instances
Table 25.67 Patent Analysis: Distribution by Type of Patent
Table 25.68 Patent Analysis: Distribution by Patent Publication Year, Pre-2018-2024
Table 25.69 Patent Analysis: Distribution by Patent Application Year
Table 25.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Pre-2018-2024
Table 25.71 Patent Analysis: Distribution by Patent Jurisdiction
Table 25.72 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 25.73 Leading Industry Players: Distribution by Number of Patents
Table 25.74 Leading Non-industry Players: Distribution by Number of Patents
Table 25.75 Leading Individual Assignees: Distribution by Number of Patents
Table 25.76 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 25.77 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 25.78 Patent Analysis: Distribution by Patent Age
Table 25.79 CAR-T Cell Therapy: Patent Valuation
Table 25.80. Global CAR-T Cell Therapy Market, Conservative, Base and Optimistic Scenario, 2024-2035 (USD Million)
Table 25.81 CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024 and 2035
Table 25.82 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (2024-2035) (USD Million)
Table 25.83 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (2024-2035) (USD Million)
Table 25.84 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (2024-2035) (USD Million)
Table 25.85 CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (2025-2035) (USD Million)
Table 25.86 CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (2028-2035) (USD Million)
Table 25.87 CAR-T Cell Therapy Market: Distribution by Target Indication, 2024 and 2035 (USD Million)
Table 25.88 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.89 CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.90 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035) (USD Million)
Table 25.91 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.92 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma, Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.93 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) (USD Million)
Table 25.94 CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035) (USD Million)
Table 25.95 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.96 CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (2028-2035) (USD Million)
Table 25.97 CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035) (USD Million)
Table 25.98 CAR-T Cell Therapy Market for Renal transplantation: Forecasted Estimates (2030-2035) (USD Million)
Table 25.99 CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035) (USD Million)
Table 25.100 CAR-T Cell Therapy Market for Ovarian and endometrial Cancer: Forecasted Estimates (2028-2035) (USD Million)
Table 25.101 CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) (USD Million)
Table 25.102 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.103 CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (2028-2035) (USD Million)
Table 25.104 CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024 and 2035
Table 25.105 CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035) (USD Million)
Table 25.106 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (2024-2035) (USD Million)
Table 25.107 CAR-T Cell Therapy Market in Asia Pacific: Forecasted Estimates (2024-2035) (USD Million)
Table 25.108 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (2024-2035) (USD Million)
Table 25.109 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (2024-2035) (USD Million)
Table 25.110 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (2024-2035) (USD Million)
Table 25.111 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, 2024-2035(USD Million)
Table 25.112 CAR-T Cell Therapy Market for Yescarta (axicabtageneciloleucel): Sales Forecast, 2024-2035 (USD Million)
Table 25.113 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel): Sales Forecast,2024-2035 (USD Million)
Table 25.114 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121): Sales Forecast, 2024-2035 (USD Million)
Table 25.115 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38MCAR-T / JNJ-68284528 /Ciltacabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
Table 25.116 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, 2024-2035 (USD Million)
Table 25.117 CAR-T Cell Therapy Market for Carteyva (Relmacabtageneautoleucel / JWCAR029): Sales Forecast, 2024-2035, (USD Million)
Table 25.118 CAR-T Cell Therapy Market for NexCART: Sales Forecast,2024-2035, (USD Million)
Table 25.119 CAR-T Cell Therapy Market for Fucaso (Equecabtagene Autoleucel): Sales Forecast,2024-2035, (USD Million)
Table 25.120 CAR-T Cell Therapy Market for Inaticabtagene AutoleucelCNCT19 / HY001: Sales Forecast, 2024-2035 (USD Million)
Table 25.121 CAR-T Cell Therapy Market for Zevorcabtagene autoleucel (CT053): Sales Forecast, 2024-2035 (USD Million)
Table 25.122 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, 2027-2035 (USD Million)
Table 25.123 CAR-T Cell Therapy Market for CAR-T-CD19 cells: Sales Forecast, 2026-2035 (USD Million)
Table 25.124 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, 2029-2035 (USD Million)
Table 25.125 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, 2028-2035 (USD Million)
Table 25.126 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, 2029-2035 (USD Million)
Table 25.127 CAR-T Cell Therapy Market for CRG-02121 cells: Sales Forecast, 2030-2035 (USD Million)
Table 25.128 CAR-T Cell Therapy Market for CT041: Sales Forecast, 2030-2035, (USD Million)
Table 25.129 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, 2032-2035, (USD Million)
Table 23.130 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast,2028-2035 (USD Million)
Table 25.131 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, 2029-2035 (USD Million)
Table 25.132 CAR-T Cell Therapy Market for AUTO1: Sales Forecast,2029-2035 (USD Million)
Table 25.133 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T): Sales Forecast, 2025-2035 (USD Million)
Table 25.134 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T): Sales Forecast, 2029-2035 (USD Million)
Table 25.135 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, 2026-2035 (USD Million)
Table 25.136 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, 2028-2035 (USD Million)
Table 25.137 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, 2027-2035 (USD Million)
Table 25.138 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, 2028-2035 (USD Million)
Table 25.139 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, 2028-2035 (USD Million)
Table 25.140 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, 2028-2035 (USD Million)
Table 25.141 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, 2028-2035 (USD Million)
Table 25.142 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, 2029-2035 (USD Million)
Table 25.143 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, 2029-2035 (USD Million)
Table 25.144 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, 2030-2035 (USD Million)
Table 25.145 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, 2029-2035 (USD Million)
Table 25.146 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T /TAA05: Sales Forecast, 2030-2035 (USD Million)
Table 25.147 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, 2028-2035 (USD Million)
Table 25.148 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, 2030-2035 (USD Million)
Table 25.149 CAR-T Cell Therapy Market for CTX110: Sales Forecast,2030-2035 (USD Million)
Table 25.150 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, 2030-2035 (USD Million)
Table 25.151 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, 2030-2035 (USD Million)
Table 25.152 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, 2030-2035 (USD Million)
Table 25.153 CAR-T Cell Therapies Market: Distribution by Key Players
Table 25.154 CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, 2024-2035 (USD Million)
Table 25.155 CAR-T Cell Therapies Market: Janssen Sales Forecast, 2024-2035 (USD Million)
Table 25.156 CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, 2024-2035 (USD Million)
Table 25.157 CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, 2024-2035 (USD Million)
Table 25.158 CAR-T Cell Therapies Market: Novartis Sales Forecast, 2024-2035 (USD Million)

List of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trial Analysis
Figure 4.3 Executive Summary: Funding and Investments
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Strategies Employed for the Redirection of T-Cells
Figure 5.2 T-Cell Manufacturing: General Procedure
Figure 5.3 Development History of CAR-T cells
Figure 5.4 Structure of Chimeric Antigen Receptor
Figure 5.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 5.6 CAR-T Cell Therapies: Development Process
Figure 5.7 Challenges Associated with CAR-T-Cell Therapies
Figure 6.1 CAR-T Cell Therapies: Distribution by Stage of Development
Figure 6.2 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 6.2 CAR-T Cell Therapies: Distribution by Target Antigen
Figure 6.3 CAR-T Cell Therapies: Distribution by Target Indication
Figure 6.4 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 6.5 CAR-T Cell Therapies: Distribution by Stage of Development and Therapeutic Area
Figure 6.6 CAR-T Cell Therapies: Distribution by Source of T-cells
Figure 6.7 CAR-T Cell Therapies: Distribution by Stage of Development and Source of T-cells
Figure 6.8 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 6.9 CAR-T Cell Therapies: Distribution by Dosage Regimen
Figure 6.10 CAR-T Cell Therapies: Distribution by Target Patient Population
Figure 6.11 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 6.12 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 6.13 CAR-T Cell Therapies Developers: Distribution by Year of Establishment
Figure 6.14 CAR-T Cell Therapies Developers: Distribution by Company Size
Figure 6.15 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Region)
Figure 6.16 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Country)
Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.3 CAR-Construction: Distribution by Generation of CAR
Figure 7.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.5 CAR-Construction: Distribution by Type of Virus Used
Figure 7.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Figure 8.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2017-2024
Figure 8.2 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Pre- 2017-2024
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2017-2023
Figure 8.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 8.8 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 8.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 8.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 8.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 8.13 Leading Industry Players: Distribution by Number of Registered Trials
Figure 8.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 8.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 9.1 KOL Analysis: Distribution by Type of Organization
Figure 9.2 KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 KOL Analysis: Distribution by Qualification
Figure 9.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 9.5 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 Most Prominent KOLs: Distribution by RA Score
Figure 9.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015- 2022
Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5. Most Popular Therapies: Distribution by Number of Partnerships
Figure 11.6. Most Active Industry Players: Distribution by Number of Partnerships
Figure 11.7. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 11.8. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 11.8. Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Pre-2014-2024

Figure12.2 Funding and Investment Analysis: Distribution by Amount Invested, Pre-2014-2024 (USD Million)

Figure12.3 Funding and Investment Analysis: Distribution by Type of Funding

Figure12.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)

Figure12.5 Year-wise Distribution of Amount Invested by Type of Funding, 2018-2024

Figure 12.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 12.7 Funding and Investment Analysis: Distribution of Funding Instances by Geography (Country)
Figure 12.8 Most Active Players: Distribution by Funding Instances
Figure 12.9 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2018-2024
Figure 13.3 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2017-2024
Figure 13.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2018-2024
Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.6 Patent Analysis: Distribution by CPC Symbols
Figure 13.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 13.8 Leading Industry Players: Distribution by Number of Patents
Figure 13.9 Leading Non-industry Players: Distribution by Number of Patents
Figure 13.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 13.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.13 Patent Analysis: Distribution by Patent Age
Figure 13.14 CAR-T Cell Therapy: Patent Valuation
Figure 14.1 Steps for Manufacturing Cell Therapies
Figure 14.2 Centralized Manufacturing: Process Model
Figure 14.3 Decentralized Manufacturing: Process Model
Figure 14.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 14.5 Cell Therapy: Challenges and Drivers
Figure 14.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 14.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 14.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 15.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 16.1. CAR-T Cell Therapies: Market Drivers
Figure 16.2. CAR-T Cell Therapies: Market Restraints
Figure 16.3. CAR-T Cell Therapies: Market Opportunities
Figure 16.4. CAR-T Cell Therapies: Market Challenges
Figure 17.1. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.2. Global CAR-T Cell Therapy Market, 2024-2035: Conservative Scenario (USD Million)
Figure 17.3. Global CAR-T Cell Therapy Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 18.1. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024 and 2035
Figure 18.2. CAR-T Cell Therapy Market for CD19: Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3. CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.4. CAR-T Cell Therapy Market for CD20: Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.5. CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (2025-2035) (USD Billion)
Figure 18.6. CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (2028-2035) (USD Billion)
Figure 19.1. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024 and 2035
Figure 19.2. CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3. CAR-T Cell Therapy Market for CAR-T Cell Therapies Market for Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.4. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.5. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.6. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma and Large B-cell Lymphoma: Forecasted Estimates (2024-2035 (USD Billion)
Figure 19.7. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) (USD Billion)
Figure 19.8. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.9. CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.10. CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.11. CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035) (USD Billion)
Figure 19.12. CAR-T Cell Therapy Market for Renal Transplantation: Forecasted Estimates (2030-2035) (USD Billion)
Figure 19.13. CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035) (USD Billion)
Figure 19.14. CAR-T Cell Therapy Market for Ovarian / Endometrial Cancer: Forecasted Estimates (2028-2035) (USD Billion)
Figure 19.15. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.16. CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.17. CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
Figure 20.2. CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3. CAR-T Cell Therapy Market in Europe: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.4. CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.5. CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.6. CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.7. CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, 2024-2035 (USD Million)
Figure 21.2 CAR-T Cell Therapy Market for Yescarta (axicabtagene ciloleucel): Sales Forecast, 2024-2035 (USD Million)
Figure 21.3 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel): Sales Forecast, 2024-2035 (USD Million)
Figure 21.4 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121): Sales Forecast, 2024-2035 (USD Million)
Figure 21.5 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
Figure 21.6 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, 2024-2035 (USD Million)
Figure 21.7 CAR-T Cell Therapy Market for Carteyva (Relmacabtagene autoleucel / JWCAR029): Sales Forecast, 2024-2035, (USD Million)
Figure 21.8 CAR-T Cell Therapy Market for NexCART: Sales Forecast, 2024-2035, (USD Million)
Figure 21.9 CAR-T Cell Therapy Market for Fucaso (Equecabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
Figure 21.10 CAR-T Cell Therapy Market for Inaticabtagene Autoleucel CNCT19 / HY001: Sales Forecast, 2024-2035 (USD Million)
Figure 21.11 CAR-T Cell Therapy Market for Zevorcabtagene autoleucel (CT053): Sales Forecast, 2024-2035 (USD Million)
Figure 21.12 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, 2027-2035 (USD Million)
Figure 21.13 CAR-T Cell Therapy Market for CAR-T-CD19 cells: Sales Forecast, 2026-2035 (USD Million)
Figure 21.14 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, 2029-2035 (USD Million)
Figure 21.15 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, 2028-2035 (USD Million)
Figure 21.16 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, 2029-2035 (USD Million)
Figure 21.17 CAR-T Cell Therapy Market for CRG-02121 cells: Sales Forecast, 2030-2035 (USD Million)
Figure 21.18 CAR-T Cell Therapy Market for CT041: Sales Forecast, 2030-2035, (USD Million)
Figure 21.19 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, 2032-2035, (USD Million)
Figure 21.20 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast, 2028-2035 (USD Million)
Figure 21.21 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, 2029-2035 (USD Million)
Figure 21.22 CAR-T Cell Therapy Market for AUTO1: Sales Forecast, 2029-2035 (USD Million)
Figure 21.23 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T): Sales Forecast, 2025-2035 (USD Million)
Figure 21.24 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T): Sales Forecast, 2029-2035 (USD Million)
Figure 21.25 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, 2026-2035 (USD Million)
Figure 21.26 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, 2028-2035 (USD Million)
Figure 21.27 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, 2027-2035 (USD Million)
Figure 21.28 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, 2028-2035 (USD Million)
Figure 21.29 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, 2028-2035 (USD Million)
Figure 21.30 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, 2028-2035 (USD Million)
Figure 21.31 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, 2028-2035 (USD Million)
Figure 21.32 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, 2029-2035 (USD Million)
Figure 21.33 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, 2029-2035 (USD Million)
Figure 21.34 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, 2030-2035 (USD Million)
Figure 21.35 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, 2029-2035 (USD Million)
Figure 21.36 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T / TAA05: Sales Forecast, 2030-2035 (USD Million)
Figure 21.37 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, 2028-2035 (USD Million)
Figure 21.38 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, 2030-2035 (USD Million)
Figure 21.39 CAR-T Cell Therapy Market for CTX110: Sales Forecast, 2030-2035 (USD Million)
Figure 21.40 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, 2030-2035 (USD Million)
Figure 21.41 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, 2030-2035 (USD Million)
Figure 21.42 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, 2030-2035 (USD Million)
Figure 22.1. CAR-T Cell Therapies Market: Distribution by Key Players
Figure 22.2. CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, 2024-2035 (USD Million)
Figure 22.3. CAR-T Cell Therapies Market: Janssen Sales Forecast, 2024-2035 (USD Million)
Figure 22.4. CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, 2024-2035 (USD Million)
Figure 22.5. CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, 2024-2035 (USD Million)
Figure 22.6. CAR-T Cell Therapies Market: Novartis Sales Forecast, 2024-2035 (USD Million)
Figure 23.1. Channels Used for Promotional Campaigns
Figure 23.2. Promotional / Marketing Strategy: Product Website Analysis
Figure 23.3. Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 23.4. Product Website Analysis: Kymriah, Messages for Patients
Figure 23.5. Product Website Analysis: Kymriah, Patient Support Program
Figure 23.6. Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 23.7. Product Website Analysis: Yescarta, Messages for Patients
Figure 23.8. Product Website Analysis: Yescarta, Kite Konnect
Figure 23.9. Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 23.10. Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 23.11. Product Website Analysis: Tecartus, Messages for Patients
Figure 23.12. Product Website Analysis: Tecartus, Kite Konnect
Figure 23.13. Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 23.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 23.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 23.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 23.17 Product Website Analysis: Abecma, Messages for Patients
Figure 23.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 23.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 23.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 23.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 24.1 Concluding Remarks: Market Landscape
Figure 25.2 Concluding Remarks: Clinical Trial Analysis
Figure 25.3 Concluding Remarks: Funding and Investment Analysis
Figure 25.4 Concluding Remarks: Patent Analysis
Figure 25.5 Concluding Remarks: Market Sizing and Opportunity Analysis

Product Code: RA100389

CAR T-cell therapy market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Antigens (CD19, BCMA, CD20, CD19/22, and Other Target Antigens), Target Indication (Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, and Others), Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World), Sales Forecast of Drugs and Leading Players

The CAR T Cell Therapy Market is valued at USD 4.6 billion in 2024 growing at a CAGR of 20% during the forecast period 2024-2035.

Cancer stands as a leading cause of mortality worldwide, with the World Health Organization (WHO) reporting 10 million cancer-related deaths in 2020 alone. Projections suggest that by 2040, the global cancer burden will escalate, adding an estimated 27.5 million new cases, placing immense physical, emotional, and financial strain on affected individuals, families, communities, and national health systems. Currently, conventional treatment modalities such as chemotherapy, radiation therapy, and surgery are utilized for various cancers. However, despite the array of treatment options aimed at controlling disease progression and halting the spread of malignant cells, achieving lasting remission remains challenging. To cater to the limitations of conventional treatments, active initiatives have been launched to develop more targeted anti-cancer therapies. Among these, CAR T cell therapies have emerged as a promising option due to their ability to eliminate tumor cells with minimal treatment-related side effects. Immunotherapies leverage the body's immune system or its components to combat cancer. Various classes of immunotherapies, including therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors, and certain whole cell-based therapies, have emerged as an alternative for cancer management and treatment.

CAR-T cell therapy, a recent addition to anticancer interventions, has shown significant success alongside targeted antibody-based therapeutics like monoclonal and conjugated antibodies. This highly specific form of cell therapy, harnessing the versatile effector machinery of the human immune system, has revolutionized cancer treatment globally. Ongoing research in this field continues to uncover novel molecular targets, bolstering the research pipelines of companies in this domain. With a growing number of CAR T cell therapies under development and entering the market, the CAR T cell therapy market is poised to become one of the most valuable segments within the biopharmaceutical industry.

Key Market Segments

Target Indication

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Generalized Myasthenia Gravis
Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma
Ovarian Cancer
Renal Cell Carcinoma
Others

Target Antigen

CD19

BCMA

CD19 / CD22

Others

Key Geographical Regions

North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa
Rest of the World

Research Coverage:

A detailed analysis of the current market landscape of CAR-T cell therapies with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, this chapter also includes developer landscape analysis based on the relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).
Comprehensive assessment of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
A comprehensive assessment of the completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
An insightful analysis highlighting the key opinion leaders (KOLs) featuring an assessment of the principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Elaborate company profiles of leading players in this domain. Each company profile includes a company overview and brief description of the product portfolio, technology portfolio, recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
An analysis of different types of partnership that have been inked between several stakeholders in this domain, on various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
An analysis of the funding and investment analysis that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
An elaborate assessment of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
An in-depth analysis of various factors that can influence the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
Comprehensive predictions of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).
Comprehensive projections of the current and future CAR T-cell therapy market across types of target antigen, such as CD19, BCMA, CD19 / CD22 and others.
Detailed projections of the current and future CAR T cell therapy market across leading players.
Detailed projections of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.
A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH(R)), Axicabtagene ciloleucel (YESCARTA(R)), Brexucabtagene Autoleucel (TECARTUS(TM)), Lisocabtagene maraleucel (Breyanzi(R)), Idecabtagene Vicleucel (Abecma(TM)), Ciltacabtagene Autoleucel (CARVYKTI(TM)) and others.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Alaunos Therapeutics
Autolus
Abelzeta Pharma
Bluebird Bio
Bristol Myers Squibb
Carsgen Therapeutics
Cellectis
Gilead Sciences
Innovative Cellular Therapeutics
Kuur Therapeutics
Noile-Immune Biotech
Novartis
Shanghai GeneChem
Sinobioway Cell Therapy
Takara Bio
Wellington Zhaotai Therapies

Table Of Contents

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of T-cell Immunotherapies
- 5.2.1. Historical Evolution
- 5.2.2. Key Considerations for Developing T-cell Immunotherapies
- 5.2.3. Strategies Employed for the Redirection of T-cells
- 5.2.4. Manufacturing of Engineered T-cells
5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
- 5.3.1. Development History
- 5.3.2. Structure of CAR
  - 5.3.2.1. Ectodomain
  - 5.3.2.2. Transmembrane (TM) Domain
  - 5.3.2.3. Endodomain
- 5.3.3. Development of CAR-T Cells
- 5.3.4. Universal CAR-T Cells
- 5.3.5. Route of Administration
- 5.3.6. Challenges Associated with CAR-T Cell Therapies
  - 5.3.6.1. Competitive Risks
  - 5.3.6.2. Clinical Risks
  - 5.3.6.3. Regulatory Risks
  - 5.3.6.4. Commercial Risks
5.4. Concluding Remarks

6. CAR-T CELL THERAPIES: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Market Landscape
- 6.2.2. Analysis by Stage of Development
- 6.2.3. Analysis by Type of Therapy
- 6.2.4. Analysis by Target Antigen
- 6.2.5. Analysis by Target Indication
- 6.2.6. Analysis by Therapeutic Area
- 6.2.7. Analysis by Stage of Development and Therapeutic Area
- 6.2.8. Analysis by Source of T-cells
- 6.2.9. Analysis by Stage of Development and Source of T-cells
- 6.2.10. Analysis by Route of Administration
- 6.2.11. Analysis by Dosage Regimen
- 6.2.12. Analysis by Target Patient Population
- 6.2.13. Most Active Industry Players: Analysis by Number of Therapies
- 6.2.14. Most Active Non-Industry Players: Analysis by Number of Therapies
6.3. CAR-T Cell Therapies: Overall Developer Landscape
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS

7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Popular Target Antigens
- 7.2.1. Popular Targets for Hematological Malignancies
- 7.2.2. Popular Targets for Solid Tumors
7.3. CAR-T Therapies: CAR Construct Analysis
- 7.3.1. Analysis by Generation of CAR
- 7.3.2. Analysis by Type of scFv Antibody Used
- 7.3.3. Analysis by Type of Virus Used
- 7.3.4. Analysis by Type of Gene Transfer Method Used
- 7.3.5. Analysis by Type of Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
- 8.3.1. Analysis by Trial Registration Year
- 8.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
- 8.3.3. Analysis by Trial Phase
- 8.3.4. Analysis of Enrolled Patient Population by Trial Phase
- 8.3.5. Analysis by Trial Registration Year and Trial Phase
- 8.3.6. Analysis by Trial Status
- 8.3.7. Analysis by Patient Gender
- 8.3.8. Analysis by Therapeutic Area
- 8.3.9. Analysis by Study Design
- 8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 8.3.13. Analysis by Geography

9. KEY OPINION LEADERS

9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
- 9.4.1. Analysis by Type of Organization
- 9.4.2. Analysis by Affiliated Organization
- 9.4.3. Analysis by Geographical Location of KOLs
- 9.4.4. KOL Activeness versus KOL Strength
- 9.4.5. Most Prominent KOLs: Analysis by RA score
- 9.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. COMPANY PROFILES

10.1. Chapter Overview
10.2. Autolus
10.3. Bluebird Bio
10.4. Bristol Myers Squibb
10.5. CARsgen Therapeutics
10.6. Cellectis
10.7. Gilead Sciences
10.8. Innovative Cellular Therapeutics
10.9. Noile-Immune Biotech
10.10. Novartis
10.11. Sinobioway Cell Therapy
10.12. Takara Bio
10.13. Wellington Zhaotai Therapies

11. PARTNERSHIPS AND COLLABORATIONS

11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapies: Partnerships and Collaborations
- 11.3.1. Analysis by Year of Partnership
- 11.3.2. Analysis by Type of Partnership
- 11.3.3. Analysis by Year and Type of Partnership
- 11.3.4. Analysis by Type of Partner
- 11.3.5. Most Popular Therapies: Analysis by Number of Partnerships
- 11.3.6. Most Active Industry Players: Analysis by Number of Partnerships
- 11.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
- 11.3.8. Analysis by Geography
  - 11.3.8.1. Intercontinental and Intracontinental Agreements
  - 11.3.8.2. International and Local Agreements

12. FUNDING AND INVESTMENTS ANALYSIS

12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapies: Funding and Investment Analysis
- 12.3.1. Analysis by Year of Funding
- 12.3.2. Analysis of Amount Invested
- 12.3.3. Analysis by Type of Funding
- 12.3.4. Analysis by Amount Invested and Type of Funding
- 12.3.5. Analysis by Amount Invested by year and Type of Funding Analysis by Type of Investor
- 12.3.6. Analysis by Geography
- 12.3.7. Most Active Players
- 12.3.8. Leading Investors: Analysis by Number of Funding Instances

13. PATENT ANALYSIS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. CAR-T Cell Therapies: Patent Analysis
- 13.3.1. Analysis by Patent Publication Year
- 13.3.2. Analysis by Patent Application Year
- 13.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
- 13.3.4. Analysis by Patent Jurisdiction
- 13.3.5. Analysis by CPC Symbols
- 13.3.6. Analysis by Type of Applicant
- 13.3.7. Leading Industry Players: Analysis by Number of Patents
- 13.3.8. Leading Non-Industry Players: Analysis by Number of Patents
- 13.3.9. Leading Patent Assignees: Analysis by Number of Patents
13.4. Patent Benchmarking Analysis
- 13.4.1. Analysis by Patent Characteristics
13.5. Patent Valuation
13.6. Leading Patents by Number Of Citations

14. CASE STUDY: CELL THERAPY MANUFACTURING

14.1. Chapter Overview
14.2. Overview of Cell Therapy Manufacturing
14.3. Cell Therapy Manufacturing Models
- 14.3.1. Centralized Manufacturing Model
- 14.3.2. Decentralized Manufacturing Model
14.4. Scalability of Cell Therapy Manufacturing Processes
- 14.4.1. Scale-Up
- 14.4.2. Scale-Out
14.5. Types of Cell Therapy Manufacturers
14.6. Key Challenges Related to Manufacturing of Cell Therapies
14.7. Key Considerations for Cell Therapy Manufacturing
- 14.7.1. Characterization
- 14.7.2. Cost of Goods
14.8. Automation of Cell Therapy Manufacturing Process
14.9. Cell Therapy Manufacturing Supply Chain
14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
14.11. Regulatory Landscape
14.12. Future Perspectives

15. COST PRICE ANALYSIS

15.1 Chapter Overview
15.2. Factors Contributing to the High Price of Cell / Gene Therapies
15.3. Pricing Models for T-cell Immunotherapies
- 15.3.1. Based on Associated Costs
- 15.3.2. Based on Availability of Competing Products
- 15.3.3. Based on Patient Population
- 15.3.4. Based on Opinions of Industry Experts
15.4. Reimbursement related Considerations for T-cell Immunotherapies
- 15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL CAR-T CELL THERAPY MARKET

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035), till 2035
17.4. Scenario Analysis
- 17.4.1. Conservative Scenario
- 17.4.2. Optimistic Scenario
17.5. Key Market Segmentations

18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. CAR-T Cell Therapies Market: Distribution by Type Target Antigen, 2024 and 2035
- 18.3.1. CART-T Cell Therapies Market for CD19: Forecasted Estimates (2024-2035)
- 18.3.2. CART-T Cell Therapies Market FOR BCMA: Forecasted Estimates (2024-2035)
- 18.3.3. CART-T Cell Therapies Market FOR CD20: Forecasted Estimates (2024-2035)
- 18.3.4. CART-T Cell Therapies Market for CD19 / CD22: Forecasted Estimates (2025-2035)
- 18.3.5. CAR-T Cell Therapies Market for Other Target Antigens: Forecasted Estimates (2028-2035)
18.4. Data Triangulation and Validation

19. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapies Market: Distribution by Target Indication, 2024 and 2035
- 19.3.1. CAR-T Cell Therapies Market for Multiple Myeloma: Forecasted Estimates (2024-2035)
- 19.3.2. CAR-T Cell Therapies Market for Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
- 19.3.3. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035)
- 19.3.4. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
- 19.3.5. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma and Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
- 19.3.6. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia/ B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035)
- 19.3.7. CAR-T Cell Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035)
- 19.3.8. CAR-T Cell Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (2024-2035)
- 19.3.9. CAR-T Cell Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (2028-2035)
- 19.3.10. CAR-T Cell Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035)
- 19.3.11. CAR-T Cell Therapies Market for Renal Transplantation: Forecasted Estimates (2030-2035)
- 19.3.12. CAR-T Cell Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035)
- 19.3.13. CAR-T Cell Therapies Market for Ovarian / Endometrial cancer: Forecasted Estimates (2028-2035)
- 19.3.14. CAR-T Cell Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035)
- 19.3.15. CAR-T Cell Therapies Market for Follicular Lymphoma: Forecasted Estimates (2024-2035)
- 19.3.16. CAR-T Cell Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (2028-2035)
19.6. Data Triangulation and Validation

20. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024 and 2035
- 20.3.1. CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035)
- 20.3.2. CAR-T Cell Therapy Market for Europe: Forecasted Estimates (2024-2035)
- 20.3.3. CAR-T Cell Therapy Market for Asia-Pacific: Forecasted Estimates (2024-2035)
- 20.3.4. CAR-T Cell Therapy Market for Latin America: Forecasted Estimates (2024-2035)
- 20.3.5. CAR-T Cell Therapy Market for Middle East and North Africa: Forecasted Estimates (2024-2035)
- 20.3.6. CAR-T Cell Therapy Market for Rest of the World: Forecasted Estimates (2024-2035)
20.4. Data Triangulation and Validation

21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Commercialized CAR-T Cell Therapies: Sales Forecast
- 21.3.1. Kymriah (Tisagenlecleucel-T) Sales Forecast
- 21.3.2. Yescarta (axicabtagene ciloleucel) Sales Forecast
- 21.3.3. Tecartus (Brexucabtagene Autoleucel) Sales Forecast
- 21.3.4. Abecma (Idecabtagene Vicleucel / bb211211) Sales Forecast
- 21.3.5. CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel) Sales Forecast
- 21.3.6. BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast
- 21.3.7. Carteyva (Relmacabtagene autoleucel / JWCAR0219) Sales Forecast
- 21.3.8. NexCART Sales Forecast
- 21.3.9. Fucaso (Equecabtagene Autoleucel) Sales Forecast
- 21.3.10. Inaticabtagene Autoleucel CNCT19 / HY001Sales Forecast
- 21.3.11. Zevorcabtagene autoleucel (CT053) Sales Forecast
21.4 Clinical CAR-T Cell Therapies: Sales Forecast
- 21.4.1. CAR-BCMA T cells Sales Forecast
- 21.4.2. CAR-T-CD19 Cells Sales Forecast
- 21.4.3. Descartes-08 Sales Forecast
- 21.4.4. Zamtocabtagene Autoleucel (MB-CART21019.1) Sales Forecast
- 21.4.5. CAR-T ddBCMA Sales Forecast
- 21.4.6. CRG-02121 cells Sales Forecast
- 21.4.7. CT041 Sales Forecast
- 21.4.8. ALLO-501A / ALLO-501 Sales Forecast
- 21.4.9. ALLO-605 Sales Forecast
- 21.4.10. Descartes-25 Sales Forecast
- 21.4.11. AUTO1 Sales Forecast
- 21.4.12. AUTO3 (CD19/2121 CAR-T) Sales Forecast
- 21.4.13. AUTO4 (CD19/2121 CAR-T) Sales Forecast
- 21.4.14. CD19-CAR-T Sales Forecast
- 21.4.15. Humanized CD19-CAR-T Sales Forecast
- 21.4.16. IM19 CAR-T Sales Forecast
- 21.4.17. CCT301 CAR-T Sales Forecast
- 21.4.18. CARCIK-CD19 Sales Forecast
- 21.4.19. CD123 CAR-T cells Sales Forecast
- 21.4.20. BCMA CAR-T Sales Forecast
- 21.4.21. CD19/CD22-CAR-T Sales Forecast
- 21.4.22. GC012F (Dual CAR-BCMA-19) Sales Forecast
- 21.4.23. CD19/CD210-CART Sales Forecast
- 21.4.24. CD7 CAR-T Sales Forecast
- 21.4.25. Anti-FLT3 CAR-T / TAA05 Sales Forecast
- 21.4.26. Anti-ALPP CAR-T Cells Sales Forecast
- 21.4.27. WU CART 007 Sales Forecast
- 21.4.28. CTX110 Sales Forecast
- 21.4.29. TX2100-TR101 Sales Forecast
- 21.4.30. ALETA-001 Sales Forecast
- 21.4.31. PBCAR0191 Sales Forecast
21.5. Data Triangulation and Validation

22. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. CAR-T Cell Therapies: Leading Players
- 22.3.1. Gilead Sciences Sales Forecast
- 22.3.2. Bristol Myers Squibb Sales Forecast
- 22.3.3. Novartis Sales Forecast
- 22.3.4. Janssen Sales Forecast
- 22.3.5. JW Therapeutics Sales Forecast
22.4. Data Triangulation and Validation

23. PROMOTIONAL ANALYSIS

23.1. Chapter Overview
23.2. Channels Used for Promotional Campaigns
23.3. Summary of Product Website Analysis
23.4. Summary of Patient Support Services and Informative Downloads
23.5. Kymriah: Promotional Analysis
- 23.5.1. Drug Overview
- 23.5.2. Product Website Analysis
  - 23.5.2.1. Message for Healthcare Professionals
  - 23.5.2.2. Message for Patients
  - 23.5.2.3. Informative Downloads
- 23.5.3. Patient Support Services
23.6. Yescarta: Promotional Analysis
- 23.6.1. Drug Overview
- 23.6.2. Product Website Analysis
  - 23.6.2.1. Message for Healthcare Professionals
  - 23.6.2.2. Message for Patients
  - 23.6.2.3. Informative Downloads
- 23.6.3. Patient Support Services
23.7. Tecartus: Promotional Analysis
- 23.7.1. Drug Overview
- 23.7.2. Product Website Analysis
  - 23.7.2.1. Message for Healthcare Professionals
  - 23.7.2.2. Message for Patients
  - 23.7.2.3. Informative Downloads
- 23.7.3. Patient Support Services
23.8. Breyanzi: Promotional Analysis
- 23.8.1. Drug Overview
- 23.8.2. Product Website Analysis
  - 23.8.2.1. Message for Healthcare Professionals
  - 23.8.2.2. Message for Patients
  - 23.8.2.3. Informative Downloads
- 23.8.3. Patient Support Services
23.9. Abecma: Promotional Analysis
- 23.9.1. Drug Overview
- 23.9.2. Product Website Analysis
  - 23.9.2.1. Message for Healthcare Professionals
  - 23.9.2.2. Message for Patients
  - 23.9.2.3. Informative Downloads
- 23.9.3. Patient Support Services
23.10. Carvykti: Promotional Analysis
- 23.10.1. Drug Overview
- 23.10.2. Product Website Analysis
  - 23.10.2.1. Message for Healthcare Professionals
  - 23.10.2.2. Message for Patients
  - 23.10.2.3. Informative Downloads
- 23.10.3. Patient Support Services

24. EXECUTIVE INSIGHTS

24.1. Chapter Overview
24.2. Atara Biotherpeutics
- 24.2.1. Interview Transcript
24.3. Glycostem Therapeutics
- 24.3.1. Interview Transcript
24.4. Gracell Biotechnologies
- 24.4.1. Interview Transcript
24.5. TxCell
- 24.5.1 Interview Transcript
24.6. Kite Pharma
- 24.6.1. Interview Transcript
24.7. Celyad
- 24.7.1. Interview Transcript
24.8. Waisman Biomanufacturing
- 24.8.1. Interview Transcript
24.9. Theravectys
- 24.9.1. Interview Transcript
24.10. Changhai Hospital
- 24.10.1. Interview Transcript
24.11. Changhai Hospital
- 24.11.2. Interview Transcript

CAR-T細胞療法市場（第5版）：業界動向と世界の予測（～2035年） - 標的抗原別、適応症別、主要地域別、薬剤売上予測、主要企業

CAR T-cell therapy market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Antigen, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 CAR-T細胞療法：市場情勢

第7章 重要な洞察

第8章 臨床試験の分析

第9章 主要なオピニオンリーダー

第10章 企業プロファイル

第11章 パートナーシップとコラボレーション

第12章 資金調達と投資の分析

第13章 特許分析

第14章 ケーススタディ：細胞療法の製造

第15章 原価分析

第16章 市場への影響分析：促進要因、抑制要因、機会、課題

第17章 世界のCAR-T細胞療法市場

第18章 CAR-T細胞療法市場、標的抗原別

第19章 CAR-T細胞療法市場、適応症別

第20章 CAR-T細胞療法市場：主要地域別

第21章 CAR-T細胞療法市場：薬剤売上予測

第22章 CAR-T細胞療法市場：主要企業の売上予測

第23章 プロモーション分析

第24章 エグゼクティブ洞察

第25章 結論

第26章 付録I：表形式データ

第27章 付録II：企業および団体一覧

第28章 付録III：資金および投資のリスト

List of Tables

List of Figures

CD19

BCMA

CD19 / CD22

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. CAR-T CELL THERAPIES: MARKET LANDSCAPE

7. KEY INSIGHTS

8. CLINICAL TRIAL ANALYSIS

9. KEY OPINION LEADERS

10. COMPANY PROFILES

11. PARTNERSHIPS AND COLLABORATIONS

12. FUNDING AND INVESTMENTS ANALYSIS

13. PATENT ANALYSIS

14. CASE STUDY: CELL THERAPY MANUFACTURING

15. COST PRICE ANALYSIS

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

17. GLOBAL CAR-T CELL THERAPY MARKET

18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN

19. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION

20. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS

21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS

22. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS

23. PROMOTIONAL ANALYSIS

24. EXECUTIVE INSIGHTS

25. CONCLUDING REMARKS

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

28. APPENDIX III: LIST OF FUNDING AND INVESTMENTS

第1章序文

第2章調査手法

第3章経済およびその他のプロジェクト特有の考慮事項

第4章エグゼクティブサマリー

第5章イントロダクション

第7章重要な洞察

第8章臨床試験の分析

第9章主要なオピニオンリーダー

第10章企業プロファイル

第11章パートナーシップとコラボレーション

第12章資金調達と投資の分析

第13章特許分析

第14章ケーススタディ：細胞療法の製造

第15章原価分析

第16章市場への影響分析：促進要因、抑制要因、機会、課題

第17章世界のCAR-T細胞療法市場

第23章プロモーション分析

第24章エグゼクティブ洞察

第25章結論

第26章付録I：表形式データ

第27章付録II：企業および団体一覧

第28章付録III：資金および投資のリスト